{
  "docId": "019de073-3cb6-7521-8cc2-fe64231d84c9",
  "docSlug": "d538949ee3add2afed287b359e626655",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 25 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 25,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide presents a balanced view, showing both efficacy and significant safety/tolerability concerns for the competitor drug.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/11",
  "deckHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9",
  "deckJsonHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json",
  "deckAnchorHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.68,
        "x": 0.29,
        "y": 0.54
      },
      "kind": "callout",
      "text": "Arikayce Boxed Warnings: Associated with an increased risk of respiratory conditions... Other common side effects: dysphonia, cough, ototoxicity, upper airway irritation, musculoskeletal pain, fatigue, diarrhea and nausea",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bad7036e-8d17-4cf3-a7e0-92936202daa7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.02,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "Arikayce (Inhaled liposomal amikacin): first and only FDA-approved NTM lung disease drug. Arikayce is associated with a high discontinuation rate and increased adverse events versus SoC therapy alone",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6da19e88-246b-47de-85c0-bce2fe3a5175",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.68,
        "x": 0.29,
        "y": 0.14
      },
      "kind": "table",
      "text": "CONVERT Study Parameter | Arikayce | Control. Efficacy: Culture-converted by month 6 (29% vs 9%). Safety: Withdrawn from study (20% vs 9%), Upper respiratory adverse events (18% vs 2%), Ototoxicity (17% vs 10%)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b2c51bd-1b0b-4b2a-935b-d36acf4b7bcb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.4,
        "x": 0.29,
        "y": 0.06
      },
      "kind": "title",
      "text": "Arikayce Pivotal Study (CONVERT) Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fb603a2-2a4e-413d-9af3-a7b9cb4b24df",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "d2e3fb02-9b5a-4ffa-8f98-5e1a321198b3",
      "evidence": "The slide presents a table with data from the CONVERT study.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}